Key result
Abnormal HbA1c is linked to ~17% higher in-hospital mortality in COVID-19 patients.
Why the study?
Patients with hyperglycemia tend to be susceptible to COVID-19, but the association of HbA1c levels with clinical outcomes in COVID-19 patients was unclear.
Are abnormal HbA1c levels, undiagnosed diabetes status, and prior anti-hyperglycaemic treatments associated with in-hospital all-cause mortality in patients hospitalized with COVID-19?
Cohort (n=922)
No
Are abnormal HbA1c levels, undiagnosed diabetes status, and prior anti-hyperglycaemic treatments associated with in-hospital all-cause mortality in patients hospitalized with COVID-19?
Answers are grounded in this paper and cite their sources.
Both low (3%-4.9%) and elevated (≥6%) HbA1c levels, as well as previously undiagnosed diabetes, are associated with increased in-hospital mortality in COVID-19 patients, whereas prior oral anti-hyperglycaemic therapy in known diabetics is associated with lower mortality.
Patients with hyperglycemia tend to be susceptible to Coronavirus disease 2019 (COVID-19). However, the association of HbA1c level with outcome of COVID-19 patients was unclear. We performed a retrospective study of 2880 cases of COVID-19 admitted in Tongji Hospital, Wuhan, China, among which 922 had detected the HbA1c levels. We found that COVID-19 patients with either lower levels of HbAlc (3%-4.9%) or higher levels of HbAlc (≥6%) were associated with elevated all-cause mortality. Meanwhile, we observed that HbAlc levels were highly correlated with haemoglobin (Hb) and total cholesterol (TC) (P < .0001), moderately correlated with albumin (ALB) and high-sensitive C reaction protein (hs-CRP) (0.0001 < P<.001), and relatively low correlated with low-density lipoprotein cholesterol (LDL-C) (.001 < P<.01). These associated cofactors might together contribute to the clinical outcome of COVID-19 patients. Furthermore, the mortality was higher in COVID-19 patients with newly diagnosed diabetes mellitus (DM) compared with COVID-19 patients with history of DM. Moreover, in patients with history of DM, the mortality was decreased in patients treated with anti-hyperglycaemic drugs. In summary, our data showed that the in-hospital mortality was increased in COVID-19 patients with lower or higher levels of HbAlc. Meanwhile, initiation of appropriate anti-hyperglycaemic treatment might improve the clinical outcome in COVID-19 patients.
No takes yet. Share an insight, caveat, or question.
Yuan et al. (2021) conducted a cohort in COVID-19 (n=922). Glycosylated haemoglobin (HbA1c) level vs. HbA1c 5%-5.9% (normal reference range) was evaluated on In-hospital all-cause mortality (OR 1.171, 95% CI 1.026-1.337, p=<0.001). Abnormal HbA1c levels were associated with elevated in-hospital all-cause mortality in COVID-19 patients compared to HbA1c 5%-5.9%.
Synapse has enriched 10 related papers. Consider them for comparative context: